Photo Credit: romanzaiets
The following is a summary of “An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy,” published in the January 2025 issue of Ophthalmology by Hammer et al.
Researchers conducted a retrospective study to analyze complications linked to heavy silicone oil use in managing inferior proliferative vitreoretinopathy (PVR).
They analyzed 20 eyes treated with vitrectomy for inferior PVR using heavy silicone oil (Densiron 68) between March 2021 and October 2022 at Oxford Eye Hospital. Complications were grouped into categories such as intraocular pressure changes, inflammation, lens-related issues, and oil emulsification or migration. Visual outcomes and surgical success rates were evaluated.
The results showed the pressure spikes exceeding 30 mmHg occurred within 14 days post-surgery in cases with Densiron tamponade, particularly among individuals previously using glaucoma medications. Glaucoma drugs were increased in 45% of individuals during tamponade, with 20% requiring long-term medication adjustments post-removal. Cataract progression was observed in all phakic cases, while 25% of pseudophakic cases exhibited posterior capsule opacification. Inflammatory complications, including anterior uveitis, were rare, and cystoid macular oedema was transient. No unexplained acute vision loss occurred following Densiron removal. The anatomical success rate at 30 days post-removal was 70%. Mean (± SD) best-corrected visual acuity improved from 1.04 (± 0.79) logMAR pre-tamponade to 0.85 (± 0.62) during tamponade and 0.50 (± 0.51) after tamponade.
Investigators concluded the outcomes with Densiron 68 aligned with prior findings for inferior PVR, while intraocular pressure and lens-related complications often required further management, and inflammatory complications were rare during 3-month tamponade durations.
Source: bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-024-03834-7